Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius
This article was originally published in The Pink Sheet Daily
Executive Summary
The Boston-area company will no longer rely as heavily on the antibiotic Cubicin, once it takes out its partner on a second marketed drug and, separately, a clinical-stage antibiotics company. The deals give Cubist territorial rights to Optimer’s Dificid for C. diff and Trius’s tedizolid for Gram-positive infections for $535 million and $707 million, respectively, plus CVRs.
You may also be interested in...
Cubicin Becomes Blockbuster, As Cubist Passes on Adynxx Acquisition
The antibiotic developer said it will look to grow its portfolio of marketed products from three to four in 2014. Long-term it’s looking to do more acquisitions, perhaps with tax strategy in mind, but backed away from an option to acquire pain company Adynxx.
Cubist Pushes Trius Drug Forward As Cubicin Comes Up Short
The antibiotic drug maker is already making advantageous moves after closing one of its two most recent acquisitions, even as its highest-revenue product sees stalled growth.
Next Up For Cubist: A Future That Includes Optimer, Trius
Cubist Pharmaceuticals will strengthen its position in the challenging antibiotic market with the acquisitions of two rivals, Optimer Pharmaceuticals and Trius Therapeutics. But it was Cubist’s current strength that allowed it to get those deals done on favorable, risk-sharing terms.